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A B S T R A C T
The favorable outcome of in vivo and ex vivo gene therapy approaches in several Lysosomal Storage Diseases
suggests that these treatment strategies might equally benefit GM2 gangliosidosis. Tay-Sachs and Sandhoff
disease (the main forms of GM2 gangliosidosis) result from mutations in either the HEXA or HEXB genes en-
coding, respectively, the α- or β-subunits of the lysosomal β-Hexosaminidase enzyme. In physiological condi-
tions, α- and β-subunits combine to generate β-Hexosaminidase A (HexA, αβ) and β-Hexosaminidase B (HexB,
ββ). A major impairment to establishing in vivo or ex vivo gene therapy for GM2 gangliosidosis is the need to
synthesize the α- and β-subunits at high levels and with the correct stoichiometric ratio, and to safely deliver the
therapeutic products to all affected tissues/organs.
Here, we report the generation and in vitro validation of novel bicistronic lentiviral vectors (LVs) encoding for
both the murine and human codon optimized Hexa and Hexb genes. We show that these LVs drive the safe and
coordinate expression of the α- and β-subunits, leading to supranormal levels of β-Hexosaminidase activity with
prevalent formation of a functional HexA in SD murine neurons and glia, murine bone marrow-derived hema-
topoietic stem/progenitor cells (HSPCs), and human SD fibroblasts. The restoration/overexpression of β-
Hexosaminidase leads to the reduction of intracellular GM2 ganglioside storage in transduced and in cross-
corrected SD murine neural progeny, indicating that the transgenic enzyme is secreted and functional.
Importantly, bicistronic LVs safely and efficiently transduce human neurons/glia and CD34+ HSPCs, which are
target and effector cells, respectively, in prospective in vivo and ex vivo GT approaches.
We anticipate that these bicistronic LVs may overcome the current requirement of two vectors co-delivering
the α- or β-subunits genes. Careful assessment of the safety and therapeutic potential of these bicistronic LVs in
the SD murine model will pave the way to the clinical development of LV-based gene therapy for GM2 gang-
liosidosis.
1. Introduction
Sandhoff disease (SD) and Tay-Sachs disease (TSD) (the main forms
of GM2 gangliosidosis) are rare neurodegenerative lysosomal storage
disease (LSD) caused by mutations in the HEXB and HEXA genes, re-
spectively, encoding for the β- and α-subunit of the β-Hexosaminidase
enzyme (E.C.3.2.1.52; β-Hex) (Sandhoff and Harzer, 2013). HexA, an
αβ heterodimer, and HexB, a ββ homodimer, are the two major forms of
β-Hex (Gravel et al., 1991), while HexS (αα) is a minor form with
negligible catalytic activity (Ellis et al., 1975; Ikonne et al., 1975). The
lysosomal accumulation of GM2 ganglioside and related glycolipids
consequent to β-Hex deficiency is ubiquitous but particularly abundant
in CNS tissues and neurons, which undergo severe and progressive
dysfunction and death (Huang et al., 1997; Phaneuf et al., 1996; Sango
et al., 2002). In the most severe (infantile) forms of SD and TSD clinical
decline is rapid and death occurs a few years after the diagnosis (Regier
et al., 2016).
There are currently no treatments for GM2 gangliosidosis. The
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infusion of the recombinant enzyme (von Specht et al., 1979; Tsuji
et al., 2011; Matsuoka et al., 2011), pharmacological chaperones
(Maegawa et al., 2007), or drugs inhibiting the synthesis of
glycosphingolipids (Andersson et al., 2004) are ineffective in infantile
patients and provide only partial benefit in late-onset forms (von Specht
et al., 1979; Maegawa et al., 2009; Clarke et al., 2011; Tallaksen and
Berg, 2009). Transplantation of hematopoietic stem/progenitor cells
(HSPCs) ameliorates neuroinflammation and prolongs the lifespan of
Sandhoff mice (Hexb−/−; resembling symptoms and progression of the
infantile disease forms) (Sango et al., 1996) but fails to counteract GM2
storage in CNS tissues, likely because of insufficient levels of β-Hex
delivered by the HSPC-derived myeloid progeny (Norflus et al., 1998;
Wada et al., 2000). In line with these observations, allogeneic hema-
topoietic stem cell (HSC) transplant provides minimal benefit to SD and
TSD patients (Hoogerbrugge et al., 1995). An autologous HSC gene
therapy (GT) approach could overcome the limitation of allogeneic
HSCT; in fact, decreasing transplant-related side effects could enhance
the therapeutic advantage expected from vector-mediated enzyme
supra-physiological expression in HSPCs and their myeloid progeny
that repopulate the CNS, PNS, and periphery. The remarkable benefit
observed in infantile metachromatic leukodystrophy patients (MLD; a
fatal neurodegenerative LSD) upon transplantation of autologous
HSPCs engineered using lentiviral vectors (LV) to overexpress ARSA
(the enzyme missing in MLD) (Biffi et al., 2013; Sessa et al., 2016)
provides a strong rationale for translating this approch to GM2 gang-
liosidos. However, whether HSPCs can safely produce and secrete
therapeutically relevant quantities of functional HexA (the only isoform
able to degrade GM2 ganglioside) (Gravel et al., 1991) by LV-mediated
genetic manipulation is currently not known.
In vivo intracerebral (IC) GT with adeno-associated virus (AAV)-
mediated β-Hex expression ameliorates the pathology of SD mice
(Cachon-Gonzalez et al., 2014; Osmon et al., 2016) and cats (McCurdy
et al., 2015; Rockwell et al., 2015). So far, the co-delivering of two
AAVs expressing the α- and β-subunits is required to generate ther-
apeutic amounts of functional HexA (Cachon-Gonzalez et al., 2014;
Bradbury et al., 2013; Gray-Edwards et al., 2017), adding difficulties to
the prospective clinical exploitation of this treatment approach. Novel
AAVs driving the expression of both subunits (Woodley et al., 2019) or
of a hybrid subunit (Tropak et al., 2016) may address this issue.
However, the immunogenicity of AAVs (Mingozzi and High, 2013), the
potential immune response triggered by a chimeric transgene, and the
toxicity associated to AAV-mediated β-Hex overexpression in CNS tis-
sues (Golebiowski et al., 2017) demand long-term efficacy and safety
assessment in relevant animal models in view of the clinical translation
of this approach.
The negligible immunogenicity and safe integration profile in neural
tissues (Bartholomae et al., 2011; Lattanzi et al., 2014; Meneghini et al.,
2016) make LVs effective vehicles in the context of IC GT approaches
for LSDs. Importantly, the large LV packaging size allows the simulta-
neous expression of multiple genes in multicistronic constructs
(Palfi et al., 2014). Earlier studies have proposed bicistronic LVs to
achieve metabolic correction in SD human fibroblasts and murine
neurons (Arfi et al., 2005; Arfi et al., 2006). However, a comprehensive
investigation of the efficacy and safety of these vectors in relevant
murine and human cell types is lacking.
In this work, we report the generation and in vitro validation of
novel bicistronic LVs driving the safe expression of the α- and β-sub-
units of the β-Hex enzyme, leading to supranormal levels of β-Hex ac-
tivity and favoring the formation of a functional HexA in SD murine
neurons and glia, bone marrow-derived murine HSPCs, and human SD
fibroblasts. The restoration/overexpression of β-Hex leads to the re-
duction of intracellular GM2 ganglioside storage in transduced and in
cross-corrected SD murine neural progeny, demonstrating that the
transgenic enzyme is secreted and functional. Importantly, bicistronic
LVs safely and efficiently transduce human neurons/glia and CD34+
HSPCs, which model target and effector cells, respectively, in pro-
spective in vivo and ex vivo GT approaches to treat GM2 gangliosidosis.
2. Results
2.1. Design and production of mono- and bicistronic lentiviral vectors
carrying the Hexa and Hexb genes
We designed and produced four third-generation VSV-G-pseudo-
typed lentiviral vectors (LVs) encoding the murine (m) Hexa and Hexb,
and the human (h) HEXA and HEB genes under the control of the
ubiquitous human phosphoglycerate kinase (PGK) promoter. In the
bicistronic LVs, the codon-optimized genes were linked by a 2A peptide
(P2A) sequence. The different vectors were called LV.mA, LV.mB,
LV.mAB, and LV.hAB, encoding the murine β-Hex α-chain, β-chain, and
both the α- and β-chains (murine and human), respectively (Fig. 1A).
Titer and infectivity of the LV batches were in the range of 0.6–2.7*109
TU/ml and 3–7*104 TU/ng, respectively (see Materials and Methods).
2.2. Efficient and safe transduction of SD neural stem/progenitor cells by
mono- and bicistronic LVs
We used neural stem/progenitor cells (NPCs) derived from SD mice
as a relevant in vitro model to test the efficacy and safety of the mono-
and bicistronic LVs. The rationale is based on our previous results
showing that patterns of β-Hex activity, isoenzyme composition, gene
expression, and ganglioside metabolism observed during embryonic
and postnatal brain development of TSD and SD mice (Hexb−/−) are
recapitulated during the stages of TSD and SD NPC differentiation to
mature glia and neurons in vitro (Martino et al., 2009).
SD NPCs were transduced with the different LVs at 50 multiplicity of
infection (MOI 50) according to optimized protocols (Neri et al., 2011).
Untransduced (UT) SD and WT cells were used as controls. All LVs
proficiently transduced murine NPCs, as shown by the presence of in-
tegrated LV genome copies in each condition tested (vector copy
number, VCN; range 2–6) (Fig. 1B). Importantly, LV transduction did
not affect the cardinal NPC functional properties, namely proliferation,
Fig. 1. Functional characterization of LV-transduced NPCs.
(A) Schematic of mono- and bicistronic lentiviral vectors. (B) VCN values of SD NPCs transduced with the different LVs at MOI 50 or MOI 50+50 for the co-delivered
LVs. Values are the mean ± SEM; n=3 independent experiments, 5–6 replicates/group. (C) Population analysis showing long-term proliferation and stable ex-
pansion rate of WT and SD NPC lines (subculturing passages 0 to 5 shown in the graph; up to 20 days in vitro, DIV). Each point of the curves represents the
mean ± SEM; n=2–3 independent experiments, 2 NPC lines. Data were interpolated using a linear regression model and best fitted the following equation:
y= a+ bx, where y is the estimated total number of cells (in log scale), x is the time (days in vitro, DIV), a is the intercept, and b is the slope. Slope values (b) +/−
SEM are the following: WT UT, 0.178 ± 0.006; SD UT, 0.213 ± 0.005; SD B, 0.235 ± 0.008; SD A+B, 0.227 ± 0.01; SD mAB, 0.223 ± 0.005; SD hAB,
0.235 ± 0.007. Data analysed by One-way Anova followed by Dunnet's multiple comparison test. *p < .05 vs all SD lines. ns, not significant vs SD UT line. (D)
Clonogenic efficiency of WT and SD NPCs (UT and LV-transduced). Data are the mean ± SEM; n= 3 independent experiments, in duplicate. Data analysed by One-
Way Anova followed by Dunnet's multiple comparison test, ** p < .001, *** p < .0005, **** p < .0001 vs WT UT. (E) Representative pictures of WT and SD
differentiated progeny after immunofluorescence analysis using anti-Tuj1 (red), anti-GFAP (green) and anti-O4 (red) antibodies to stain neurons, astrocytes and
oligodendrocytes, respectively. Nuclei are counterstained with Hoechst (blue). Magnification: 20×. Scale bar, 50 μm. (F) Cell type composition of WT and SD (UT
and LV-transduced) differentiated cultures. Data are expressed as percentage of immunoreactive (IR) cells on total nuclei and represent the mean ± SEM of n=4
experiments, 2 coverslips/group.
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self-renewal, and multipotency. LV-transduced and UT NPCs showed
long-term proliferation when serially subcultured in the presence of
FGF2 and EGF (Gritti et al., 2009). The trend for a higher proliferation
rate observed in SD NPCs (both UT and LV-transduced) (Fig. 1C) may
reflect a higher content of stem/progenitor cells in the SD as compared
to the WT cell populations, as also suggested by the increased clono-
genic efficiency (Fig. 1D). This feature did not affect NPC multi-
potentiality. Indeed, immunofluorescence (IF) analysis using antibodies
against lineage-specific markers followed by quantification of cells
immunoreactive for the different antigens showed similar proportions
of neurons (TUJ1), astrocytes (GFAP), and oligodendrocytes (O4) in
both UT and LV-transduced NPC-derived progeny (differentiated cells,
obtained by culturing NPCs in FGF2 for 2 days and then in a mitogen-
free medium supplemented with 2% FBS for additional 5 days)
(Fig. 1E–F).
Overall these data show that transduction using mono- and bicis-
tronic LVs is well tolerated by NPCs and does not impact on their
functional features.
2.3. Stable expression of the α- and β-subunits, supranormal β-Hex activity,
and correct isoenzyme composition mediated by bicistronic LVs in SD NPCs
and progeny
We assessed the efficacy of bicistronic LVs in achieving optimal
expression of the α- and β-subunit, correct isoenzyme composition, and
restoration of β-Hex activity. To this end, we measured the mRNA ex-
pression of murine and human Hex genes, β-Hex activity and isoforms
in two NPC-derived types of cultures (UT and LV-transduced): i) a cell
population enriched in proliferating and undifferentiated cells, ob-
tained by culturing NPCs for two days in EGF+FGF2 (precursor cells);
(ii) NPC-derived mixed neuronal/glial cultures (differentiated cells; see
Fig. 1E–F).
We assessed mRNA expression by qPCR exploiting probes re-
cognizing the native or the codon-optimized sequences of the Hex
genes. The probes toward the native sequence allowed us determining:
i) the endogenous (physiological) Hexa and Hexb mRNA in untreated
(UT) WT and SD cells; ii) the total level of Hexa and Hexb mRNA
(endogenous + transgenic) in NPCs transduced with monocistronic
vectors, whose sequence is not codon-optimized (LV.mA, LV.mB); iii)
the endogenous mRNA in NPCs transduced with bicistronic vectors
(LV.mAB, LV.hAB). The probes toward the codon-optimized sequences
do not recognize the native sequences, thus detecting only the trans-
genic mRNA in cells transduced with bicistronic vectors.
UT SD precursors (Fig. 2A) and differentiated cells (Fig. 2B) showed
normal pattern of endogenous Hexa and strongly reduced levels of
endogenous Hexb mRNA expression as compared to the WT counter-
part. LV.mB-transduced SD cells displayed a significant upregulation of
total Hexb mRNA expression (≈100- and ≈20-fold the WT levels in
precursors and differentiated cells, respectively, mainly reflecting the
transgene overexpression given the low endogenous levels), without
changes in the endogenous Hexa mRNA expression. The co-delivery of
monocistronic LVs (LV.mA+LV.mB) in SD cells resulted in upregula-
tion of both genes, with a 10-fold higher expression of total Hexb as
compared to total Hexa mRNA expression (Fig. 2A–B). The expression
of transgenic Hexb and Hexa mRNAs (codon optimized sequence) was
high and comparable in SD cells transduced with the bicistronic
LV.mAB (up to 30-fold the normal levels), while a 10-fold higher ex-
pression of the codon-optimized HEXB as compared to HEXA was de-
tected in LV.hAB-transduced murine SD cells (Fig. 2A–B). Neither in
precursor nor in differentiated cells the upregulation of the murine and
human codon optimized transgenes did affect the expression level of the
endogenous Hexa and Hexb genes (Fig. 2A–B).
The advantage of bicistronic LVs as compared to the co-delivery of
monocistronic LVs in achieving stoichiometric expression of Hexa and
Hexb genes was further confirmed by assessing β-Hex enzymatic ac-
tivity in transduced cells using two artificial substrates: MUG is
hydrolysed by both α and β subunits, and therefore by HexA (αβ), HexB
(ββ), and HexS (αα); MUGS is hydrolysed only by the α subunit, and
therefore by HexA and HexS. UT SD cells show barely detectable levels
of MUG- and MUGS-related enzymatic activity (Fig. 2C, precursors;
Fig. 2D, differentiated cells). Transduction of SD cells with LV.mB was
sufficient to achieve supraphysiological level of enzymatic activity (8-
and 5-fold the WT levels for precursors and differentiated cells with
MUG, respectively) (Fig. 2C-D). Transduction with LV.mB+ LV.mA
and bicistronic LVs ensured supraphysiological enzymatic activity
(≈10–40-fold the WT levels). Of note, we detected +30% and +100%
of MUG and MUGS-related activity, respectively, in SD cells transduced
with bicistronic LVs as compared to those transduced with
LV.mA+LV.mB, resulting in close to physiological MUG/MUGS ratio
(≈2 and ≈4 in WT precursors and differentiated cells, respectively)
(Fig. 2C–D). Importantly, the supraphysiological enzymatic activity was
achieved using half the vector dose with bicistronic LVs. The pattern of
enzymatic reconstitution upon transduction with different LVs was
stable along NPC differentiation toward neurons and glia (Suppl.
Fig. 1A–B).
The chromatographic analysis corroborated the evidence of LV-
mediated β-Hex rescue/overexpression and, in combination with the
enzymatic assay through MUG and MUGS substrates, provided addi-
tional information about the subunit composition of Hex isoenzymes
(Martino et al., 2009; Martino et al., 1997; Martino et al., 2005). In our
experimental conditions HexB was eluted with the void volume from
the column, whereas HexA, HexS, and intermediate forms were re-
tained by the column and eluted with a linear gradient of NaCl
(0.0–0.5M) based on their respective isoelectric points. The chroma-
tographic profile of WT UT NPCs (Fig. 2E) showed two peaks of activity
corresponding to HexB (43% of total Hex activity) and HexA (57% of
total Hex activity) (Suppl. Table 1). The isoenzyme ratio changed in
differentiated cells, in which HexA accounted for ≈90% of total Hex
activity (Suppl. Fig. 1C; Suppl. Table 1). In SD precusors (Fig. 2F) and
differentiated cells (Suppl. Fig. 1D) the residual activity eluted with the
high concentration of NaCl might correspond to HexS, due to the ab-
sence of the β-subunit. Transduction of SD NPCs with LV.mB caused the
formation of HexB (11% of total Hex activity), HexA (36% of total Hex
activity), and an additional consistent peak of activity (53% of total Hex
activity) eluted at a lower NaCl concentration with respect to HexA and
detectable only with the MUG substrate (Fig. 2G; Suppl. Table 1). This
form might correspond to a Hex intermediate form composed of ββ
precursors that we have documented in murine brain tissues during
development and in NPCs and that we named HexI (Martino et al.,
2009). In SD NPCs transduced with LV.mA+LV.mB the overexpression
of both α and β subunits generated the formation of HexB (6% of total
Hex activity), HexA (53% of total Hex activity), HexI (22% of total Hex
activity), and HexS (9% of total Hex activity) (Fig. 2H; Suppl. Table 1).
The transduction of SD NPCs with bicistronic LV.mAB generated a high
amount of HexA (67% of total Hex activity) but little HexB (3% of total
Hex activity) and a consistent HexI (30% of total Hex activity) sug-
gesting that α and β subunits are still unbalanced (Fig. 2I; Suppl.
Table 1). Finally, transduction of SD NPCs with bicistronic LV.hAB
generated the formation of HexB (40% of total Hex activity), a small
amount of HexI (6% of total Hex activity), and HexA (54% of total Hex
activity) (Fig. 2J; Suppl. Table 1), as well as a chromatographic profile
comparable to the WT UT counterpart. These isoenzyme patterns are
maintained in differentiated cells (Suppl. Fig. 1E–F). Importantly,
Western Blot analysis revealed that LV.hAB-transduced cells showed
mature expression of the HexA and HexB proteins (Woodley et al.,
2019; Tropak et al., 2016; Sinici et al., 2013; Utsumi et al., 2002)
(Suppl. Fig. 1G).
Overall these data strongly suggest that bicistronic LVs drive a
stoichiometric expression of α and β subunits that is not fully guaran-
teed by the co-delivery of monocistronic LVs and ensure a close to
physiological reconstitution of isoenzyme composition coupled to su-
praphysiological levels of functional HexA and HexB.
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2.4. Rescue of β-Hex activity and metabolic correction in LV-transduced
and cross-corrected NPC-derived neurons and glial cells
Qualitative and quantitative IF analysis showed the expansion of the
lysosomal compartment (LAMP1) and accumulation of GM2 ganglio-
side in SD NPC-derived progeny as compared to WT counterparts
(Fig. 3A–C), with GM2-positive signal detected in both neurons and
glial cells (Fig. 3D). Transduction with LV.mB only partially reduced
GM2- and LAMP1-positive areas, which were instead normalized upon
the delivery of both the α- and β-subunits, either by bicistronic LVs or
co-delivery of the monocistronic LVs (Fig. 3A–C). These results confirm
NPC cultures as a valuable model recapitulating the GM2 storage and
lysosomal abnormalities that characterize SD pathology. In addition,
they suggest that the functional HexA enzyme generated by the si-
multaneous delivery of α- and β-subunits is sufficient to rescue the
primary biochemical and functional disease hallmarks in this in vitro
culture system.
The therapeutic efficacy of gene therapy strategies greatly relies on
the capability of genetically modified cells to secrete part of functional
lysosomal enzyme for its uptake by neighbouring enzyme-deficient cells
(metabolic cross-correction). In order to check the occurrence of cross-
correction in our system, we exposed SD NPCs and progeny (acceptor
cells) to the supernatant of WT UT or LV.mAB-transduced SD cells
(donor cells) during the differentiation process (Suppl. Fig. 2A). At the
end of the experiment, we analysed β-Hex activity and GM2 storage in
SD cross-corrected neuronal/glial progeny. Supraphysiological enzy-
matic activity in LV.mAB-transduced SD NPCs (15-fold the normal)
correlated to higher enzymatic activity in the supernatant (Fig. 4A–B
and Suppl. Fig. 2B). The presence of supranormal vs. physiological le-
vels of β-Hex activity in the supernatant moderately enhanced cross-
correction, as shown by the 2-fold higher intracellular MUG-related
enzymatic activity measured in SD cross-corrected cells (Fig. 4C), to
reach up to 20% of WT activity. Of note, DEAE-cellulose chromato-
graphy showed the presence of HexB, HexI and HexA in all cross-cor-
rected SD cells, with an improved rescue of enzymatic activity in SD
cells exposed to the supernatant from LV.mAB-transduced SD cells as
compared to WT UT cells, further confirming that enzyme over-
expression enhances metabolic cross-correction of SD cells (Fig. 4D).
The 30–40% reduction of GM2 storage detected in cross-corrected SD
cells exposed to the supernatant containing physiological or supra-
physiological levels of β-Hex activity (Fig. 4E–F) suggested that i) in
this experimental in vitro setting the presence of 10–20% of normal
enzyme ameliorates SD pathology; ii) the transgenic enzyme delivered
by the bicistronic LV is as functional as the native counterpart. To
further confirm these data, we analysed the sphingolipid pattern of
untreated SD and cross-corrected neuronal/glial progeny by incubating
SD NPCs in the presence of H3-sphingosine for 48 h before adding the
supernatant collected from donor cells. Thin layer chromatography
(TLC) and quantification of radioactive bands showed a modest
(< 10%) reduction in the content of GM2 but a much stronger reduc-
tion (30–60%) in the content of its asialo form GA2 in cross-corrected
cells as compared to SD UT cells, with a clear advantage observed in the
presence of enzyme-enriched supernatant (Fig. 4G–H). The discrepancy
in GM2 reduction observed by TLC as compared to immunofluorescence
with the anti-GM2 antibody (Fig. 4E) may reflect the peculiarities and
intrinsic limitations of these very different assays in capturing the
complex ganglioside metabolism occurring in neural cell types.
Collectively, these data support the occurrence of GM2 clearance by
supernatants from WT and transduced cells (with an advantage of the
latter), indicating that the functional transgenic enzyme is secreted,
recaptured by SD cells, and correctly delivered to lysosomes.
2.5. Efficient transduction and enzymatic rescue of murine HSPCs by
bicistronic LVs
The optimization of gene transfer protocols ensuring the production
and secretion of (supra) physiological HexA levels from HSPCs and
progeny is mandatory to exploit the potential of autologous HSC GT
approaches for GM2 gangliosidosis. To this end, we tested the efficacy
of bicistronic LVs in achieving safe β-Hex rescue/overexpression in
lineage negative (Lin-) HSPCs isolated from the BM of SD mice.
We transduced Lin- HSPCs with the different LVs at MOI 50.
Transduced cells were plated in a methylcellulose-based medium for
the colony forming cell (CFC) assay. The leftover was plated for dif-
ferentiation in liquid cultures (LC). Fourteen days later, colonies were
counted and LC were collected to perform VCN and β-Hex enzymatic
activity. All LVs proficiently transduced Lin- HSPCs without evident
toxicity, as shown by consistent VCN (range 2–6; Fig. 5A) and similar
numbers of colonies (Fig. 5B) detected in all the conditions. MUG- and
MUGS-related enzymatic activity was rescued to WT levels in SD cells
transduced with LV.mB+ LV.mA, LV.mAB, and LV.hAB (Fig. 5C–D; LC
and CFC). The chromatographic profiles of SD cells transduced with
LV.mB or the co-delivery of LV.mA+LV.mB showed the persistence of a
consistent HexI peak, which is absent in physiological conditions (WT
UT) (Fig. 5E–H; Suppl. Table 1). In contrast, LV.hAB-transduced SD
cells showed a pattern of isoenzyme composition resembling the phy-
siological counterpart, with a consistent presence of HexA and reduced
formation of Hex I (Fig. 5I; Suppl. Table 1). This rescue was present but
less evident in SD cells transduced with LV.mAB, which lack HexI but
still show an unbalanced HexA/HexB ratio in favour or HexA (Fig. 5J;
Suppl. Table 1).
These results showed the efficacy of bicistronic LVs in achieving
effective reconstitution of β-Hex activity and close to normal isoenzyme
composition, and suggest their potential advantage as compared to the
co-delivery of monocistronic LVs in a clinically relevant cell type for
prospective gene therapy approaches.
2.6. Enhancement of β-Hex activity in human neural and hematopoietic
cells
We next assessed whether bicistronic LVs were effective and safe in
clinically-relevant human cell types, namely neurons/glial cells and
CD34+ HSPCs, in view of their potential clinical use for in vivo and/or
ex vivo GT approaches.
Fig. 2. Gene expression, enzymatic activity and isoenzyme composition of LV-transduced NPCs.
(A–B) Expression of Hexa and Hexb mRNA in WT UT and SD (UT and LV-transduced) precursors (A) and differentiated cells (B). The mRNA expression was measured
exploiting probes recognizing specifically the native (plain bars) versus the codon-optimized (C.O.) sequences (striped bars). In UT WT and SD cells the probes toward
the native sequence detect the endogenous Hexa and Hexb mRNA; in NPCs transduced with monocistronic vectors (non C.O. sequence) the probes detect the total
mRNA (endogenous + transgenic); in NPCs transduced with bicistronic vectors encoding C.O. sequences, we use the two types of probes to distinguish the en-
dogenous (bearing the native sequence) vs. the transgenic (C.O.) mRNA. Values are the mean ± SEM and are expressed as fold versus the WT UT (set as 1). Gene
expression is normalized on GAPDH. n=3 independent experiments, 3 samples/group. Data were analysed by One-way ANOVA followed by Kruskal-Wallis multiple
comparison test; * p < .05, ** p < .01, *** p < .001, **** p < .0001 versus WT UT; § p < .05 C.O. Hexb gene vs. C.O. Hexa gene.
(C–D) MUG- and MUGS- related enzymatic activity measured in WT UT and SD (UT and LV-transduced) precursors (C) and differentiated cells (D). Data were
analysed by One-way ANOVA followed by Kruskal-Wallis multiple comparison test; * p < .05, ** p < .01, *** p < .001, **** p < .0001 versus WT UT.
(E–J) Diethylaminoethyl Cellulose (DEAE) chromatography showing the presence of HexA, HexB, HexS and HexI isoforms in WT and SD UT (E-F) and in LV-
transduced SD precursors (G-J). Enzymatic activity (expressed as nmol/min; mU MUG on the left and mU MUGS on the right) and fraction number (0.5ml) are
plotted on the y and x axis, respectively.
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Fig. 3. GM2 storage and lysosomal ex-
pansion in SD neural progeny.
Representative immunofluorescence pic-
tures (A) and quantification of im-
munoreactive area (B–C) showing GM2
storage and Lamp1 expression in SD UT
differentiated cells and rescue to physio-
logical levels (WT UT) in LV-transduced
SD cells (SD mAB, SD hAB). In A: GM2,
red; Lamp1, blue; Nuclei counterstained
with Hoechst (grey, pseudocolor).
Magnification: 40×. Scale bar, 50 μm.
Data in B–C are the mean ± SEM, n=3
experiments, 3 coverslips/experiment.
**p < .01 vs. WT, One Way Anova fol-
lowed by Kruskal-Wallis post-test. (D)
Representative immunofluorescence con-
focal merged pictures showing GM2 ex-
pression (red) in astrocytes (GFAP, green)
and neurons (TUJ1, green) of SD UT dif-
ferentiated cells and rescue to physiolo-
gical levels (WT UT) in LV.mAB-trans-
duced SD cells. Scale bar, 50 μm (upper
panels) and 10 μm (lower panels). (For
interpretation of the references to colour
in this figure legend, the reader is referred
to the web version of this article.)
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We differentiated human induced pluripotent stem cell (iPSCs) -
obtained by reprogramming of healthy donors (HD) fibroblasts - into
NPCs and differentiated progeny using a protocol that generates mixed
populations of neurons, astrocytes, and oligodendrocytes at different
stages of differentiation/maturation (Frati et al., 2018). Seven days
after plating, we exposed NPC-derived progeny to LV.hAB (MOI 2 and
MOI 5; overnight incubation). Cultures were grown for additional
7 days in order to promote neuronal and glial differentiation and allow
LV integration and transgene expression. Cultures were collected at day
(d) 14 for molecular and biochemical analysis.
LV.hAB proficiently transduced hiPSC-derived neural progeny in a
dose-dependent manner. The high VCN (range 20–30) obtained in LV-
transduced cell populations using these relatively low MOIs reflects the
presence of a variable amount of intracellular non-integrated vector in
transduced cells, which is expected since these cells do not actively
proliferate in these culture conditions (≈10% of proliferating cells at
d14 of differentiation) (Frati et al., 2018). The average composition of
NPC-derived cultures at d14 is: ≈ 15–20% neurons (TUJ1), 5–10%
astrocytes (GFAP), 10–20% of oligodendrocytes (CNPase), 30–40% of
neural progenitors (nestin+, A2B5+) (Frati et al., 2018). By qualita-
tive immunofluorescence analysis we observed similar cell type com-
position and neuronal/glial morphology in UT and LV-transduced cul-
tures (Fig. 6A). LV-transduced cells display a dose-dependent increase
of β-Hex activity (up to 3 and 6-fold the normal levels, respectively, at
MOI 2 and MOI 5; Fig. 6B), with a physiological MUG/MUGS ratio
(≈11:1 and ≈10:1 in HD- and LV-transduced NPCs, respectively). The
higher enzymatic activity measured in the supernatant of LV.hAB-
transduced human NPC progeny as compared to untransduced coun-
terparts (Fig. 6C and Suppl. Fig. 3) point to the potential advantage of
transgene overexpression in enhancing the availability of β-Hex in the
extracellular space in the context of in vivo gene therapy platforms.
Importantly, the chromatographic profile of LV-transduced cells closely
resembled the physiological counterpart (NPCs UT: HexB ≈ 47%;
HexI≈ 5%; HexA ≈ 48% of total Hex activity; LV.hAB NPCs: HexB
≈43%; HexI ≈15%; HexA ≈ 42% of total Hex activity) (Fig. 6D–E;
Suppl. Table 1). Overall, these data suggest that LV.hAB-mediated
transduction and β-Hex overexpression are well tolerated by iPSC-de-
rived neural progeny and result in efficient production and secretion of
functional HexA.
We used commercially available CD34+ HSPCs isolated from
healthy donors (n=2; donor#1 and donor#2), which underwent one
round of transduction using LV.hAB (MOI 100) according to described
protocols (Scaramuzza et al., 2013; Ungari et al., 2015). The VCN
measured in LV-transduced HSPC progeny after 14 days of differentia-
tion in liquid cultures (LC) was 0.66 (donor #1) and 0.42 (donor #2), in
line with previous data (Scaramuzza et al., 2013). LV-transduced cells
displayed a detectable increase of β-Hex activity (≈2-fold and ≈1.6-
fold the HD level for MUG- and MUGS-related activity, respectively;
Fig. 6F), a physiological 10:1 MUG/MUGS ratio (8:1 in UT CD34+
cells), and a normal chromatographic profile (Fig. 6G–H). In fact,
LV.hAB-transduced cells display levels of HexB (≈52% of total Hex
activity), HexI (≈11% of total Hex activity), and HexA (≈37% of total
Hex activity) comparable to those found in CD34+ UT cells (HexB
≈52%; HexI≈11%; HexA≈ 37%; Suppl. Table 1). Overall these results
provide proof of concept of the feasibility and efficacy of using bicis-
tronic LVs to achieve safe β-Hex overexpression in human HSPCs.
2.7. Rescue of enzymatic activity in SD fibroblasts by bicistronic LV.hAB
We sought to obtain proof of concept of LV.hAB-mediated rescue of
enzymatic activity and isoenzyme composition in fibroblasts (hFF) de-
rived from a SD patient (healthy donor –HD- fibroblasts were used as
controls). SD fibroblasts were incubated overnight with LV.hAB (MOI
10 and MOI 20) and sub-cultured for 2 passages before being collected
for molecular and biochemical analysis.
The VCN measured in LV.hAB-transduced SD fibroblasts ranged
between 0.5 and 2.
LV-transduced SD fibroblasts displayed full rescue of β-Hex activity
(Fig. 7A), a 8:1 MUG/MUGS ratio, and a physiological isoenzyme
composition (HD UT: HexB ≈40%; HexI ≈20%; HexA ≈40% of total
Hex activity; SD LV.hAB: HexB ≈23%; HexI ≈20%; HexA ≈57% of
total Hex activity) (Fig. 7B–D; Suppl. Table 1). Western Blot analysis
revealed mature expression of the HexA and HexB proteins in LV.hAB-
transduced SD fibroblasts (Fig. 7E) with a pattern of α- and β-subunit
composition comparable to that observed in HD UT counterparts
(Suppl. Fig. 4).
Importantly, LV.hAB-mediated enzymatic rescue led to clearance of
GM2 storage, which is present in untreated SD fibroblasts (Fig. 7F).
Collectively, these results indicate that the bicistronic LV.hAB drives
the synthesis and secretion of functional β-Hex enzyme in SD fibro-
blasts, highlighting its biological efficacy in a patient-derived cell type.
3. Discussion
Gene therapy (GT) is a promising approach to ensure a steady
supply of β-Hex to CNS and other affected tissues potentially for the
recipient's lifetime, with the capacity to comprehensively address GM2
gangliosidosis pathology. Hematopoietic stem cell gene therapy (HSC
GT), in which autologous HSPCs are engineered with LVs to overexpress
a functional enzyme, provides benefit in a similar LSD, metachromatic
leukodystrophy (Biffi et al., 2013; Sessa et al., 2016), supporting the
rationale for applying a similar approach to GM2 gangliosidosis. Pro-
spectively, coupling the benefit of HSC GT with the timely enzymatic
supply to CNS tissues provided by LV-mediated intracerebral (IC) GT is
expected to provide a synergistic effect (Ricca et al., 2015). The ex-
perimental work described here contributes to the prospective clinical
development of such approaches by addressing key and still unexplored
feasibility, efficacy, and safety issues related to the (over)expression of
a functional β-Hex enzyme using optimized bicistronic LVs in relevant
murine and human neural and hematopoietic cell types that are target
(neurons/glia) or effector cells (HSPCs) in in vivo and ex vivo GT ap-
proaches.
The peculiar biological features, coupled to scalable manufacture
for clinical applications, make LVs safe and effective vehicles in the
Fig. 4. Metabolic cross-correction of SD NPCs and progeny.
(A–B) Supraphysiological enzymatic activity in the cell pellet (A) and supernatant (Sup; B) of LV.mAB-transduced SD differentiated cells as compared to WT UT
counterparts (donor cells) assessed by measuring MUG- and MUGS-related enzymatic activity. Unpaired Student t-test, ** p < .01 vs. WT UT (C) Enhanced MUG-
related enzymatic activity in cross-corrected SD cells exposed to the Sup of LV.mAB-transduced (enzyme overexpressing) donor cells as compared to those exposed to
the Sup of WT UT counterparts. Hex activity is expressed as fold to SD UT. Data are the mean ± SEM, n=2 independent experiments. Unpaired Student t-test, *
p < .05 vs. WT UT (D). DEAE chromatography showing the presence of HexA, HexB, and HexI isoforms in SD cross-corrected cells exposed to the Sup of WT UT or
LV.mAB-transduced SD cells. Enzymatic activity (expressed as nmol/min; mU MUG on the left and mU MUGS on the right) and fraction number (0.5ml) are plotted
on the y and x axis, respectively. (E–F) Representative immunofluorescence pictures (E) and quantification of immunoreactive area (F; normalized on total nuclei)
showing a 30–40% reduction of GM2 storage in SD cross-corrected cells. In E: GM2, red; Lamp1, green; nuclei counterstained with Hoechst (blue); magnification:
20×. Scale bar, 50 μm. Data in F are expressed as fold to SD UT and represent the mean ± SEM. n=2 independent experiments. (G–H) Representative digital
autoradiography (G) and quantification (H) of radioactive lipids obtained from SD UT or SD cross-corrected cells. Data in H are expressed as percentage of
radioactivity (DPM/mg prot) of the single species on the total radioactivity associated with gangliosides and neutral sphingolipids, respectively. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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context of in vivo and ex vivo GT approaches for LSDs, as suggested by
pre-clinical studies (Ungari et al., 2015; Ricca et al., 2015) and results
of recent Phase I/II clinical trials (Biffi et al., 2013; Sessa et al., 2016).
Importantly, the large LV cargo capacity (Palfi et al., 2014; Grieger and
Samulski, 2012) may overcome the issue of vector co-delivery or the
need of developing small size chimeric proteins, facilitating the devel-
opment of GT strategies for GM2 gangliosidosis. Based on these pre-
mises, we developed bicistronic LV constructs in which the murine and
human genes coding for the α- and β-subunits are linked by a P2A self-
cleaving peptide, which allows for stoichiometric and concordant ex-
pression of the two genes (Szymczak-Workman et al., 2012). In order to
ameliorate the stability of the transcript and improve enzyme expres-
sion, we took advantage of codon optimization. Indeed, recoding the
transgene to optimize transcription and translation has already been
demonstrated to improve LVs titers as well as protein production and
the efficacy of therapies, i.e., for chronic granulomatous disease, hae-
mophilia A and B, SCID, GLD and MLD (Biffi et al., 2013; Ungari et al.,
2015; Chiriaco et al., 2014; Cantore et al., 2015).
Our results show safe and effective bicistronic LV-mediated trans-
duction of murine SD NPCs and differentiated progeny, a cellular model
that recapitulates the pattern of β-Hex expression and isoenzymatic
composition and display consistent GM2 storage and lysosomal ex-
pansion, two main LSD pathological hallmarks (Ballabio and
Gieselmann, 2009). All LVs proficiently transduced SD NPCs, resulting
in multiple copies of integrated LV genome/cell (VCN). The comparable
VCN measured in cells transduced with either bicistronic LVs (MOI 50)
or co-delivered monocistronic LVs (MOI 50 ± 50) may reflect an early
counter selection of the double-transduced cells achieving an excessive
vector load. The use of bicistronic LVs has the potential to decrease the
LV dose needed for effective transduction, further improving the safety
profile. All LV-transduced NPCs cells maintained normal proliferation
and multipotency over time in vitro, confirming previous data showing
safe LV-mediated gene transfer in NPCs derived from LSD murine
models (Neri et al., 2011; Lattanzi et al., 2010).
Our comprehensive molecular and biochemical analysis showed
that bicistronic LVs outperform the co-delivered monocistronic LVs in
achieving stoichiometric expression of the α- and β-subunits in SD NPCs
and progeny. Indeed, while the co-delivery of monocistronic LVs - and
even the single delivery of LV.mB - was sufficient to boost β-Hex ac-
tivity, only transduction with bicistronic LVs resulted in close-to-phy-
siological MUG- and MUGS- related activity and balanced HexA/HexB
expression. Importantly, transduction with bicistronic LV.hAB resulted
in supranormal levels of β-Hex activity and correct isoform expression
in iPSC-derived human neurons/glial cells derived from healthy donors.
We have previously shown that therapeutic LVs mediated enzymatic
rescue of neurons and glial cells derived from MLD patients (Meneghini
et al., 2017) and GLD NHP (Meneghini et al., 2016). The formation of
mature HexA and HexB transgenic proteins in LV.hAB-transduced
murine SD NPCs and progeny as well as in SD patient-derived fibro-
blasts suggests the biological efficacy of the bicistronic LV.hAB in SD
pathology. In addition, these data support the advantage of this bicis-
tronic construct (hexb-P2A-hexa) as compared to the one described
previously (hexb-IRES-hexa), which led to an excess of ββ at the ex-
penses of αβ formation in SD fibroblasts (Arfi et al., 2005). Based on
these premises, we expect a similar safety and efficacy profile in SD
patient-derived neural cells, which should be ultimately tested as they
represent the target of prospective intracerebral GT approaches.
The production and secretion of (supra) physiological HexA from
HSPCs and progeny is mandatory to exploit the potential of autologous
HSC GT for the treatment of GM2 gangliosidosis. We leveraged on a LV
GT platform that has been effectively applied to (over)express ther-
apeutic transgenes (including lysosomal enzymes) in HSPCs, both in
pre-clinical studies (Ungari et al., 2015; Visigalli et al., 2010) and in the
context of autologous ex vivo HSC GT Phase I/II clinical trials in patients
with MLD (Biffi et al., 2013; Sessa et al., 2016), WAS (Aiuti et al., 2013;
Ferrua et al., 2019), β-thalassemia (Marktel et al., 2019) and MPS I
(ClinicalTrials.gov Identifier: NCT03488394). Our results extend the
applicability of this platform to bicistronic LVs expressing the α- and β-
subunits of β-Hex enzyme, which showed a clear advantage as com-
pared to co-delivered monocistronic LVs in achieving safe and effective
reconstitution/moderate overexpression of β-Hex activity and ameli-
oration/normalization of isoenzyme composition in both murine (Lin-)
SD HSPCs and human CD34+ cells from healthy donors. As compared
to neural cells, HSPCs are poorly permissive to LV gene transfer, due to
quiescence and the presence or enhanced expression of innate or
adaptive restriction factors acting at different steps of the transduction
pathway (Santoni de Sio et al., 2006; Wang et al., 2014). Robust gene
transfer thus requires cell pre-stimulation with activating cytokines and
high concentrations of LV with high specific infectivity. Our data
showing VCN < 1 in CD34+ cells transduced with LV.hAB at MOI 100
(one round of transduction) are in line with previous results obtained
by using lab-grade and clinical-grade LV preparations (Scaramuzza
et al., 2013). Current efforts toward improvement of transduction
protocols include the use of new drugs able to counteract restriction
factors and enhance gene transfer (Wang et al., 2014; Petrillo et al.,
2015; Zonari et al., 2017; Petrillo et al., 2018; Heffner et al., 2018) and
optimized culture conditions to increase the yield and fitness of trans-
duced cells (Boitano, 2011; Wagner et al., 2016; Cutler et al., 2013;
Watts et al., 2013; Fares et al., 2017). Some of these improvements have
been introduced in recent experimental clinical protocols and could
become standard procedure in prospective clinical development of HSC
GT for GM2 gangliosidosis.
The therapeutic benefit expected by in vivo and/or ex vivo GT ap-
proaches for LSDs not only rely on the direct correction of endogenous
CNS cells or pervasive replacement of tissue-resident myeloid cells with
HSPC-derived functional counterparts, but also on the release of part of
functional enzyme by genetically modified cells for its uptake by
neighbouring enzyme-deficient cells (metabolic cross-correction). The
extent of secretion and reuptake varies among the different lysosomal
enzymes and in different cells types (Markmann et al., 2015; Klein
et al., 2009). Previous works reported cross-correction of SD fibroblasts
(Arfi et al., 2005), but limited information is available for neural and
hematopoietic cells (Ohsawa et al., 2005; Oya et al., 2000; Tsuji et al.,
2005). We detected 10–20% of normal β-Hex activity in cross-corrected
SD neurons/glia cultures exposed to supranormal enzymatic activity.
This rescue was sufficient to achieve a 30–60% reduction of GM2 and
GA2 storage in these in vitromodels, as evaluated using different assays.
Optimization of LV and transgene design may improve vector particle
distribution and enhance enzyme bioavailability in the context of GT
approaches (Sorrentino et al., 2013; Gleitz et al., 2018). Tailored ex-
periments testing β-Hex activity in the CSF, CNS, PNS, and peripheral
organs of SD mice undergoing in vivo and/or ex vivo GT approaches
Fig. 5. Transduction of mono- and bicistronic LVs in murine HSPCs results in rescue of enzymatic activity and isoenzyme composition.
(A) VCN values in LV-transduced HSPCs (MOI 50 or 50+50 for co-delivered monocistronic LVs). Values are the mean ± SEM; n=2–3 independent experiments;
3–4 samples/group. (B) Colony forming cell (CFC) assay shows similar number of colonies in all the conditions tested. p > .05 vs.WT UT, One-way Anova followed
by Dunnet's post-test. (C–D) Rescue of MUG- and MUGS-related enzymatic activity to physiological levels (WT UT) in LC (C) and colonies (D) generated from SD
HSPCs transduced with LV.mHexb + LV.mHexa, LV.mAB, and LV.hAB. (E–J) DEAE chromatography performed on LC from untransduced HSPCs (WT and SD UT; E,
F) and LV-transduced SD HSPCs (LV.mAB, LV.hAB) shows the presence of HexA and HexB isoforms and a strong reduction of HexI in LV.hAB- and LV.mAB-
transduced HSPCs (I–J). HexI is still present in SD HSPCs transduced with LV.mB (G) or with the co-delivered monocistronic LVs (LV.mA+LV.mB; H). Enzymatic
activity (expressed as nmol/min; mU MUG on the left and mU MUGS on the right) and fraction number (0.5ml) are plotted on the y and x axis, respectively.
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Fig. 6. Bicistronic LV.hAB rescues β-Hex activity in human
neural and hematopoietic stem/progenitor cells from healthy
donors.
(A) Representative immunofluorescence confocal pictures
showing similar cell type composition in neural progenitors
(Nestin, green; A2B5, red), neurons (TUJ1, green), and astrocytes
(GFAP, red) in UT and LV-transduced hiPSC-derived neural cul-
tures. Scale bar, 50 μm in all panels (shown in the bottom left
panel). (B–C) LV.hAB-transduced iPSC-derived neurons/glial
cells display dose-dependent increase of MUG- and MUGS-related
enzymatic activity in the cell lysate (B) and in the supernatant
(C) as compared to untreated (UT) counterparts. MOI, multi-
plicity of infection. (D–E) DEAE chromatography shows com-
parable isoenzyme composition in LV.hAB-transduced human
NPCs (E; MOI 2) as compared to UT counterparts (D). (F)
LV.hAB-transduced CD34+ HSPCs cells display 1.5- to 2-fold
increase in MUG- and MUGS-related enzymatic activity as com-
pared to UT counterparts. (G–H) DEAE chromatography per-
formed on LC from UT (G) and LV.hAB-transduced CD34+ cells
(H) show comparable isoenzyme composition. (For interpreta-
tion of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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could definitely assess whether LV-transduced endogenous CNS cells
and/or HSPC-derived myeloid progeny replacing the tissue resident
microglia and macrophages secrete sufficient levels of β-Hex to ensure
effective cross-correction and full metabolic rescue of endogenous en-
zyme-deficient neurons/glia of SD mice (and prospectively patients).
4. Conclusion
We here demonstrated the safe and effective profile of novel bicis-
tronic LVs in driving robust β-Hex expression with preferred formation
of a functional HexA (αβ) in SD murine NPCs, HSPCs and progeny, as
well as in human SD fibroblasts, normal iPSC-derived neurons/glia, and
CD34+ HSPCs. We expect that human SD HSPCs and neurons/glia
could benefit even more from this approach for the sustained enzyme
activity mediated by gene transfer that could restore cellular functions
and promote the cross-correction of affected cells. Altogether, these
findings provide a strong rationale for considering these bicistronic LVs
as promising candidates for the clinical translation of in vivo and ex vivo
GT approaches for GM2 ganglisidosis.
5. Material and methods
5.1. Lentiviral vectors
5.1.1. Cloning
In all lentiviral vectors (LVs) the expression of transgenes was
driven by the human phosphoglycerate kinase (hPGK) promoter.
Briefly, hexa and hexb murine cDNAs were inserted in the backbone of
LV using BamH1-Sal1 unique restriction sites. The plasmids codifying
for LV.mAB and LV.hAB were synthetized by Gene Script (New Jersey,
USA) using the murine and the human codon-optimized sequence. Each
plasmid encodes for the cDNA of murine or human hexb, P2A sequence
(5′- GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGAC
GTGGAGGAGAACCCTGGACCT-3′), and murine or human hexa, in this
order.
5.1.2. Production and titration
VSV-pseudotyped third-generation LVs were produced by transient
four-plasmid cotransfection into 293T cells and purified by ultra-
centrifugation, as described (Amendola et al., 2005; Vigna et al., 2005).
Expression titers of vectors were estimated on human cells (293T) by
limiting dilution and calculation of the copies of integrated vector
(VCN) per cell by quantitative PCR. Specifically, titer was calculated as
VCN×number of plated cells× dilution of vector. Vector expression
titer was expressed as transducing units (TU)/ml. Vector particle was
measured by HIV-1 gag p24 antigen immunocapture (NEN Life Science
Products). Vector infectivity was calculated as the ratio between titer
and particle and expressed as TU/ng of p24 (Titer/p24).
Titer and infectivity for the different LVs are the following:
LV.mA – Titer: 0.68*109 TU/ml; Infectivity: 3.78*104 TU/ng
LV.mB – Titer: 1.15*109 TU/ml; Infectivity: 7.47*104 TU/ng
LV.mAB – Titer: 1.66*109 TU/ml; Infectivity: 3.31*104 TU/ng
LV.hAB – Titer: 2.69*109 TU/ml; infectivity: 4.41*104 TU/ng
5.2. Establishment of murine NPC lines
Murine NPC cell lines were established as previously described
(Gritti et al., 2009). Briefly, 3-month-old WT and SD mice were an-
aesthetised by intraperitoneal injection of Avertin (2,2,2-Tri-
bromoethanol; 0.25mg/g body weight). Brains were removed and
transferred in a Petri dish containing PBS+Glucose (0,6%)+ Peni-
cillin/Streptomicin (P/S) (1%). The olfactory bulbs were removed, a
coronal slice comprising the periventricular subventricular zone (SVZ)
of the forebrain lateral ventricles was cut and the periventricular tissue
was carefully dissected. After enzymatic digestion, tissue was dis-
sociated and single cells were plated in DMEM/F12 (1:1) medium
supplemented with EGF2 and FGF2 (20 ng/ml; growth medium) to
generate primary neurospheres that were collected and serially pas-
sages to establish NPC cultures. We established independent cell lines
from the SVZ of SD and WT mice (n=2 for each genotype). For all the
experiments, we used serially passaged NPCs (passage 5–15). All lines
underwent functional characterization (self-renewal, proliferation, and
multipotency), as described below.
5.3. Lentiviral vector-mediated gene transfer in NPCs
Serially subcultured NPCs (passages 5–10) were plated in growth
medium (proliferating conditions) in 6-well plates (30,000 cells/cm2).
Eight hours after plating cells were incubated overnight with LVs at
MOI 50. LV-containing medium was then removed, fresh medium
added, and cells incubated for additional 4–6 days to obtain neuro-
spheres that were further subcultured to establish stable LV-transduced
NPC lines. LV-transduced NPCs were analysed for their functional fea-
tures before being used for the experiments.
5.4. Functional characterization of NPCs
5.4.1. Proliferation
Long-term proliferation of the bulk NPC cultures was assessed by
generating growth curves, as previously described (Gritti et al., 2009).
Briefly, we plated 2×105 viable cells in a 25 cm2 flask (0 days in vitro-
DIV) in growth medium. At each subculture passage (every 4–5 days)
the total number of viable cells was counted, and 2×105 cells were
replated under the same conditions. This procedure was repeated for at
least 5 subculture passages. The estimated total number of cells was
calculated by multiplying the amplification rate (total number of cells
obtained at a given subculture passage/2×105) for the total number of
cells obtained at the previous passage. The total number of cells (in
log10 scale) was plotted against the DIV. Data were interpolated using a
linear regression model and best fitted the following equation:
y= a+bx, where y is the estimated total number of cells (in log scale),
x is the time (DIV), a is the intercept (constrain: 2× 105), and b is the
slope. The best-fit value, the standard error, and the 95% confidence
intervals of the slope for each dataset were calculated. The slope values
were then compared using one-way ANOVA followed by Dunnet's
multiple comparison test. Statistical significance was accepted with
P≤ .05.
Fig. 7. Bicistronic LV.hAB rescues enzymatic activity in SD fibroblasts.
(A) Transduction of SD patient–derived fibroblasts (hFF) with LV.hAB (MOI 10 and 20) rescues β-Hex activity to physiological levels. (B–D) DEAE chromatography
shows comparable isoenzyme composition in LV.hAB-transduced SD hFF (MOI 20) and untransduced healthy donor hFF (HD UT). Enzymatic activity (expressed as
nmol/min; mU MUG on the left and mU MUGS on the right) and fraction number (0.5 ml) are plotted on the y and x axis, respectively. (E) Western blot using anti-α-
and anti-β- chain antibodies shows the presence of the mature HexA (54 kDa) and HexB protein (28 kDa) in HD UT and LV.hAB-transduced but not in untransduced
SD hFF; human 293 T cells served as control. (F) Representative immunofluorescence confocal pictures showing GM2 storage and increased LAMP1 expression in SD
UT fibroblasts, which are cleared or reduced in LV.hAB-transduced counterparts (MOI 20). Fibroblasts from HD are shown for comparison. GM2, red; Actin, green;
Lamp1, blue. Nuclei are counterstained with Hoechst (white; pseudocolor). Magnification: 63×. Scale bar, 25 μm. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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5.4.2. Clonogenic assay
Serially passaged neurospheres were dissociated and cells were
plated in growth medium (1000 cells/cm2 in 48-well plates). The
number of newly formed neurospheres in each well was counted after
7 days. The ratio between the number of neurospheres obtained and the
number of plated cells (x100) is indicated as clonal efficiency.
5.4.3. Multipotency
Cells were induced to differentiate by progressive removal of
growth factors. Serially passaged NPCs were plated (40,000 cells/cm2)
onto an adhesive substrate (matrigel) in growth medium for two days.
The resulting population (precursors) was either collected for molecular
and biochemical analysis or further induced to lineage commitment and
differentiation by exposure to FGF2-containing medium for 48 h, fol-
lowed by 5 days in a mitogen-free medium containing 2% FBS, to drive
the differentiation into neurons and glia (differentiated cells). The per-
centage of neuronal and glial cells in differentiated cells was assessed
by immunofluorescence analysis and quantification using lineage-spe-
cific markers.
5.5. Isolation and transduction of murine hematopoietic stem/progenitor
cells (HSPCs)
Young adult mice (4–8weeks) were sacrificed with CO2, and bone
marrow (BM) was harvested by flushing femurs, tibias, and humeri.
Murine HSPCs were purified (lineage cell depletion kit, Miltenyi
130–090-858; LS columns, Miltenyi 130–042-401) and plated (100,000
cells/cm2) in StemSpan serum-free medium (Stemcell 09650) supple-
mented with cytokines (mSCF, 5 ng/ml; hFlt3L, 10 ng/ml; mIL3, 10 ng/
ml; TPO, 50 ng/ml; all from Peprotech) in the presence of LVs at MOI
50 for 12 h. After transduction, HSPCs were: i) washed, counted, and
seeded at a density of 4000 cells/ml in semi-solid medium (murine
Methocult, StemCell 03434). After 14 days, colonies were scored and
counted (CFC assay); ii) plated in RPMI medium (Corning 15040CVR),
10% FBS (Euroclone ECS0180L), 1% P/S (Lonza 17-602E), 1% L-glu-
tamine (Lonza 17-605E), and cytokines (mSCF, 5 ng/ml; hFlt3L, 10 ng/
ml; mIL3, 10 ng/ml; TPO, 50 ng/ml; all from Peprotech), cultured for
14 days before being collected and analysed for VCN, enzymatic ac-
tivity, and isoenzyme composition (liquid cultures, LC).
5.6. Human cells
Human cells were used according to the guidelines on human re-
search issued by the San Raffaele Scientific Institute's Ethics Committee,
in the context of the protocol TIGET-HPCT (approved 03.12.2009).
5.6.1. HSPCs
Human HSPCs from two healthy donors (umbilical cord blood-de-
rived CD34+) were purchased from Lonza (Verviers, Belgium; product
code 2C-101). Cells (80,000 cells per condition) were pre-stimulated for
12 h with the standard CB-HSPCs cytokine cocktail (hIL-6, 20 ng/μl;
hTPO, 20 ng/μl; hSCF, 100 ng/μl; hFlt3-L, 100 ng/μl) in StemSpan
serum-free medium (StemCell Technologies, Vancouver, British
Columbia, Canada) and then incubated with LV.hAB at MOI 100
overnight. Transduced HSPCs were plated in IMDM medium (Sigma
Aldrich, St Louis, MO), 10% FBS (Euroclone, Pero, Italy), penicillin
100 U/ml and streptomycin 100 μg/ml, L-glutamine 2mmol/l, and cy-
tokines (hSCF, 300 ng/μl; hIL3, 60 ng/μl; hIL6, 60 ng/μl) and cultured
for 14 days before being collected and analysed for VCN, enzymatic
activity and isoenzyme composition (liquid cultures).
5.6.2. Induced pluripotent stem cell (iPSC)-derived neural progeny
The human iPSC lines used in this work are derived from the re-
programming of HD fibroblasts obtained by the Cell Line and DNA Bank
of Patients affected by Genetic Diseases (code FFF0561980) or
purchased from Invitrogen (code C0045C). The characteristics of the
cell lines and the protocols to obtain iPSC-derived NPCs and neuronal/
glial progeny have been previously described (Frati et al., 2018). All the
cells used were mycoplasma-free (tested once every two weeks). Briefly,
iPSC-derived NPCs were cultured in proliferating medium (NPCM; basal
medium containing FGF2 and EGF), detached using Accutase and re-
plated on Matrigel-coated dishes (20,000 cells/cm2) in NPCM (d0).
During the first 4 days after plating (d4) we gradually replaced NPCM
with an increasing amount of differentiation medium (basal medium
supplemented with 10ng/ml PDGF-AA, 10ng/ml NT3, 10ng/ml IGF-1,
5ng/ml HGF, and 60ng/ml T3) to favour neural lineage commitment
and differentiation. From d4 to d13 medium was changed every other
day. At d7, cultures were incubated overnight with LV.hAB (MOI 2 and
MOI 5) supplemented with 8mg/ml Polybrene (Sigma-Aldrich, St.
Louis, MO). Then, LV-containing medium was removed, and fresh
medium added for additional 7 days. Cells were analysed at d14 for
VCN, morphology and cell type composition, enzymatic activity and
isoenzyme composition.
5.6.3. Fibroblasts
Skin fibroblasts derived from one SD patient and one healthy donor
(HD) were obtained from the Cell Line and DNA Bank of Patients af-
fected by Genetic Diseases (Institute Gaslini, Genova, Italy, http://
www.gaslini.org). Fibroblasts were plated (10,000 cells/cm2) in human
fibroblasts medium (HFM): DMEM (Life Technologies), 10% Fetal
Bovine Serum (Euroclone), 0.1mM non-essential amino acids (Life
Technologies), 1 mM Sodium Piruvate (Life Technologies), 2 mM L-
Glutamine (Lonza), 100 U/ml penicillin/streptomycin (Lonza) supple-
mented with 8mg/ml Polybrene (Sigma-Aldrich, St. Louis, MO).
Cultures at ≈70% confluence were incubated with LV.hAB (MOI 10,
MOI 20) overnight. LV-containing medium was then removed and fresh
HFM added. Cells were collected 10 days after transduction and ana-
lysed for VCN, enzymatic activity, isoenzyme composition, and im-
munofluorescence.
5.7. Quantification of vector copy number (VCN)
Genomic DNA (gDNA) from human and murine cells was extracted
from cellular pellets (Maxwell 16 Cell DNA purification kit, Promega),
following the manufacturer instructions. gDNA was quantified by 260/
280 nm optical density (OD) reading on the NanoDrop ND-1000
Spectrophotometer (Euroclone, Pero, Italy). The number of vector co-
pies integrated in the host genome (vector copy number, VCN) was
quantified by quantitative droplet dd-PCR, using the custom primers
and probes listed below. VCN were normalized to genomic DNA con-
tent, which was assessed using the murine SEMA3A or the human TELO
gene. VCN analysis by ddPCR involved quantification of target and
reference loci through the use of duplex target and reference assays. In
QuantaSoftTMsoftware, copy number was determined by calculating
the ratio of the target molecule concentration to the reference molecule
concentration, times the ploidy of reference species.
Murine endogenous gene primers and probes:
Sema3A primers/HEX probe set
• Forward primer: 5′-ACC GAT TCC AGA TGA TTG GC-3′• Reverse primer: 5′-TCC ATA TTA ATG CAG TGC TTG C-3′• HEX probe: 5′- (HEX) - AGA GGC CTG TCC TGC AGC TCA TGG-
(BHQ-1) - 3′
Human endogenous gene primers and probes:
TELO primers/Vic-TAMRA probe set
• Forward primer: 5′-GGCACACGTGGCTTTTCG-3′• Reverse primer: 5′-GGTGAACCTCGTAAGTTTATGCAA-3′• Vic-TAMRA probe: 5′-TCAGGACGTCGAGTGGACACGGTG-3′
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Transgene primers and probes:
HIV primers/FAM probe set
• Forward primer: 5′-TACTGACGCTCTCGCACC-3′• Reverse primer: 5′-TCTCGACGCAGGACTCG-3′• FAM probe: 5′-ATCTCTCTCCTTCTAGCCTC-3′
5.8. Immunofluorescence (IF)
Double-labelling immunofluorescence was performed as previously
described (Martino et al., 2009). Cultures were fixed in 4% PFA, rinsed
with PBS, incubated with blocking solution containing 10% normal
goat serum (NGS) with or without 0.1% Triton X-100 (Sigma) in PBS for
1 h at RT and incubated o/n at 4 °C with primary antibodies diluted in
blocking solution. After three washing in PBS of 5min each, antibody
staining was revealed using species-specific fluorophore-conjugated
secondary antibodies diluted in PBS+1% NGS for 1 h. Nuclei were
counterstained with Hoechst (10 μg/ml in PBS, Thermofisher). Cover-
slips were mounted on glass slides using Fluorsave (Calbiochem).
Samples incubated only with secondary antibodies were used as nega-
tive controls.
Primary antibodies: monoclonal anti-Tuj1 (1:500; Biolegend,
801202); polyclonal anti-Tuj1 (1:500; Biolegend, 802001); polyclonal
anti-GFAP (1:1000; DAKO, ZO334); monoclonal anti-GFAP (1:1000;
Millipore, MAB 3402); monoclonal anti-O4 (1:500; R&D, MAB 1326);
monoclonal anti-GM2 (1:500; TCI EUROPE, A2576); polyclonal anti-
Lamp1 (1:200; Abcam, AB24170); hybridoma anti-Lamp1 (1:300;
DSHB, 1D4B); monoclonal anti-A2B5 (1:1000; Chemicon, MAB 312r);
monoclonal anti Nestin (1:200; Millipore, MAB 353); rabbit anti-actin
(1:500; Santa-Cruz, sc-1616r).
Secondary antibodies (all from Thermo Fisher Scientific): ALEXA
488 (1:1000; anti-rabbit A11008, anti-mouse A11001); ALEXA 546
(1:2000; anti-mouse A11039); ALEXA 633 (1:500; anti-rat A21094).
5.9. Image acquisition and quantification
Coverslips were visualized with a Nikon Eclipse E600 microscope
and images were acquired at 20× or 40× magnification with Nikon DS
Ri-2 camera, using NIS-Elements F imaging software (Nikon, Japan).
Immunoreactive cells were counted in at least 5 non-overlapping fields
in each sample (> 300 cells/sample) and expressed as a percentage on
the total nuclei. Data are the mean ± SEM of two-three coverslips in
three independent experiments. Images were analysed by the ImageJ
software to quantify GM2 and LAMP1 signal intensity corresponding to
immunopositive areas (expressed in pixels). UT samples were used for
setting the threshold. The area was normalized on the number of nuclei
in the same field. The merged images were obtained using the Volocity
Software (v5.2.1; PerkinElmer- Improvision, Lexington, MA). Images
were imported into Adobe Photoshop CS4 and adjusted for brightness
and contrast.
Confocal images were acquired at 63× magnification with a Leica
TCS SP8 confocal microscope and analysed with LasX software.
5.10. Real time RT-PCR
Total RNA was extracted from cells by RNeasy mini Kit (Qiagen,
Hilden, Germany), following the manufacturer's instructions. Reverse
transcription was carried out using 1 μg of total RNA and the Quantitect
Reverse Transcriptase kit (Qiagen, Hilden, Germany). qPCR was per-
formed in Optical 96-well Fast Thermal Cycling Plates (Applied
Biosystem) on ViiATM 7 Real-Time PCR System (Applied Biosystem),
using the following thermal cycling conditions: one cycle at 95 °C for
5min, 40 cycles at 95 °C for 15 s and 60 °C for 1min, using Universal
PCR Master Mix (Applied Biosystems) and TaqMan Gene Expression
Assays (Applied Biosystems). Commercial probes and primers are listed
below. The SDS 2.2.1 software was used to extract raw data. Relative
expression of mRNA for the target genes was calculated by the com-
parative CT (ΔΔCT) method, using a housekeeping gene as control.
Briefly, ΔCt was calculated for each sample as the Ct of the gene of
interest minus the Ct of the normalizer (GAPDH). The ΔΔCt was then
determined as the ΔCt of each sample minus the average of the ΔCt of
controls. Finally, the fold change was expressed as 2^(-ΔΔCt), for each
sample.
PRIMERS AND PROBES
Gapdh Glyceraldehyde 3-phosphate dehydrogenase Mm99999915_g1
mHex a Murine Hexosaminidase α subunit Mm00599877_m1
mHex b Murine Hexosaminidase β subunit Mm01282432_m1
mHex a c.o. Murine codon-optimized Hexosaminidase α sub-
unit
Custom
mHex b c.o. Murine codon-optimized Hexosaminidase β sub-
unit
Custom
hHex a c.o. Human codon-optimized Hexosaminidase α sub-
unit
Custom
hHex b c.o. Human codon-optimized Hexosaminidase β sub-
unit
Custom
5.11. β-Hexosaminidase activity and isoenzyme composition
Enzymatic activity and isoenzyme composition was determined in
cell extracts as previously described (Martino et al., 2009; Martino
et al., 2005; Martino et al., 2002; Martino et al., 1995) and briefly
summarized here.
5.11.1. Cell extracts
Cells were harvested, washed in PBS and resuspended in 10mM
sodium phosphate buffer, pH 6.0, containing 0.1% (v/v) Igepal de-
tergent (Sigma-Aldrich, St, Louis, MO, USA), subjected to three rounds
of sonication and centrifuged at 13,400 g for 10min. All procedures
were carried out at 4 °C. Proteins were measured by the Bradford
method using bovine serum albumin as standard.
5.11.2. Enzymatic assay
Hexosaminidase activity was determined using 3mM 4-methy-
lumbelliferyl-N-acetyl-β-d-glucosaminide (MUG) and 3mM 4-methy-
lumbelliferone-6-sulfo-2-acetamido-2-deoxy-β-d-glucopyranoside
(MUGS) substrates dissolved in 0.1M citrate/0.2M disodium phosphate
buffer at pH 4.5. The enzymatic reactions were performed using 50 μl of
test sample incubated with 100 μl of substrate at 37 °C. All reactions
were stopped by adding 2.850ml of 0.2M Glycine/NaOH, pH=10.6.
Fluorescence of the liberated 4-methylumbelliferone was measured on a
Perkin Elmer LS3 spectro-fluorimeter (λ excitation 360 nm, λ emission
446 nm).
5.11.3. β-Hexosaminidase isoenzyme composition
Cell extracts were analysed by ion-exchange chromatography on
Diethylaminoethyl- (DEAE)-Cellulose. Chromatography was performed
using 0.5ml column equilibrated with 10mM sodium phosphate buffer,
pH 6.0 (buffer A). The flow rate was 0.5ml/min. Enzyme activity re-
tained by the column was eluted by a linear gradient of NaCl (0.0–0.5M
in 20ml of buffer B starting from fraction no. 20). Finally, the column
was eluted with 1.0M NaCl in buffer A. Fractions (0.5ml) were col-
lected and assayed for the Hex activity.
5.12. Cross-correction of SD NPCs and progeny
Donor cells (WT UT or LV.mAB-transduced SD NPCs) were plated on
an adhesive substrate (matrigel) in medium containing FGF2 (20,000
cell/cm2) (d0). After 48 h (d2), the supernatant (Sup) was removed and
substituted with fresh medium without mitogens containing 2% FBS.
This medium change was repeated at d4 and d6. The Sup collected at d4
and d6 was centrifuged to remove debris and used to treat acceptor cells
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(SD UT) that had been plated under the same differentiating conditions.
After a 24 h-washout with fresh medium, we collected acceptor cells
and their Sup. Enzymatic activity was measured in the Sup and pellet of
donor and acceptor cells, as described above.
5.13. Sphingolipid analysis
SD NPCs were plated on an adhesive substrate (matrigel) in medium
containing FGF2 (20,000 cell/cm2) supplemented with 12 nM of
[1−3H]-sphingosine (specific radioactivity 1.06 Ci/ mmol). After 48 h
we removed the medium and incubated cells with either fresh medium
or with the Supernatant (SUP) collected from donor cells, according to
the cross-correction protocol described above. At the end of the ex-
periment, cell lipids were extracted using the solvent system chlor-
oform:methanol:water, 2:1:0.1, by volume. Total lipids extracts were
subjected to phase separation according to Folch method with some
modifications, as previously described (Samarani et al., 2018; Valsecchi
et al., 2010). Finally, organic phases were subjected to alkaline me-
thanolysis to remove glycerophospholipids (Valsecchi et al., 2010).
Lipids contained in the organic and aqueous phases were separate by
HPTLC using the solvent system chloroform:methanol:water 110:40:6
(v:v:v) and chloroform:methanol:CaCl2 0.2%, 50: 42:11 (v: v: v), re-
spectively. Radioactive lipids were detected by digital autoradiography
performed with a Beta-Imager TRacer system (BioSpace lab) and
quantified using M3 vision software. Identification of lipids after se-
paration was assessed by co-migration with authentic radioactive lipid
standards.
5.14. Western blotting
Protein samples were extracted as described above. After boiling for
5min in loading buffer, samples containing 40 μg protein were sepa-
rated through a 4–12% gel SDS-PAGE electrophoresis. Western blotting
was performed as previously described (Martino et al., 1995). Primary
antibodies: monoclonal anti-α-subunit and polyclonal anti-β-subunit of
Hex (anti-HexA, 1:1000, LS-C197404, LSBio; anti-HexB, 1:1000, LS-
C354001, LSBio); rabbit anti calnexin, 1:5000, Sigma C4731. Im-
munodetection was performed using the Amersham ECL PlusTM kit (GE
Healthcare).
5.15. Statistics
Data were analysed with Graph Pad Prism version 8.0 for Macintosh
and expressed as the mean ± std. error of the mean (SEM). Unpaired
Student t-test and One-way or Two-Way ANOVA followed by post-tests
were used when appropriate (statistical significance: P < .05). The
number of samples and the statistical test used are indicated in the
legends of each figure.
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